Cumberland Pharmaceuticals Logo

Print Print page   Email Email page   PDF Download PDF    Add to Briefcase
« Previous Release | Next Release »



Cumberland Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 11, 2010

NASHVILLE, Tenn., Oct 28, 2010 /PRNewswire via COMTEX News Network/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it will release third quarter 2010 financial results after the market closes on Thursday, November 11, 2010. A conference call and live Internet webcast will be held on Thursday, November 11, 2010 at 5:00 p.m. Eastern Time to discuss the results.

To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 800-642-1687 (for U.S. callers) or 706-645-9291 (for international callers). The Conference ID for the rebroadcast is 21780077. The live webcast and rebroadcast can be accessed via Cumberland's website at http://investor.shareholder.com/cpix/events.cfm.

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's product portfolio includes Acetadote(R) (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor(R) (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, and Kristalose(R) (lactulose) for Oral Solution, a prescription laxative. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information on Cumberland, please visit the Company's website at www.cumberlandpharma.com.


    Investor Contact:
    Angela Novak
    Corporate Relations
    615-255-0068
    anovak@cumberlandpharma.com

    Media Contact:
    Rebecca Kirkham
    Lovell Communications
    615-297-7766
    rebecca@lovell.com


SOURCE Cumberland Pharmaceuticals Inc.

Copyright (C) 2010 PR Newswire. All rights reserved

Close window | Back to top